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was completed in February 2009. Today, after ten years of diagnosis of breast cancer, eight years after axillary recurrence and
ﬁve years after brain metastases was developed, the patient is in radiological complete response and continues treatment with
Herceptin. How long will you continue with this treatment?
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Introduction. In recent decades, the survival of Hodgkin Lymphoma (HL) has increased signiﬁcantly as a result of improved radio-
therapy techniques and the introduction of new chemotherapy schedules. It is calculated that 30% of patient relapse, particularly
the ﬁrst two years after treatment. However there is an important patient population that suffers from late relapse (LR). We report
the case of a patient who relapsed 20 years after treatment.
Material and methods. A 34 year old man was diagnosed in 1992 (when he was 15) of HL nodular sclerosis-mixed cellularity clinical
stage IIIA. He was treated with 5 cycles of MOPP-ABVD plus external beam radiotherapy (EBRT): Mantle (40Gy) inverted-Y with
spleen (15Gy). As late side effects the patient developed a subclinical Hypothyroidsm as well as effects on muscle and bone
covered with mantle ﬁeld. After 20 years in complete remission, the patient noticed a subcutaneous nodule at axillary edge of
pectoralis, less than 1cm, without evidence of B symptoms or illness to another site. Biopsy showed a lymph node inﬁltrated by
classical HL nodular sclerosis subtype. Clinical staging with complete laboratory test and PET-CT demonstrated no evidence of
disease (Stage IA). Treatment given: ABVD x2 plus involved ﬁeld EBRT 20.4Gy at 1.7Gy/fx.
Discussion and conclusion. The patient had an excellent tolerance to the treatment. Currently he is asymptomatic and in remission.
Although there is no consensus on the deﬁnition of LR in HL is necessary to encourage active monitoring of these patients beyond
5 years to detect LR. Evidence based on a literature review suggests that long-term survival was not signiﬁcantly different in
patients who relapsed 5 years after ﬁrst treatment compared with patients without relapse.
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